CIK 0001840229 · <br>Emerging growth company
MiNK Therapeutics, Inc.
Sign in to watch- Ticker
- INKT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 212-994-8250
- Business address
- 149 FIFTH AVENUE, SUITE 500, NEW YORK, NY, 10010
- Former names
- AgenTus Therapeutics, Inc., AgenTus Therapeutics, Inc.
- 4 Grant or award Director acquired 15,077 shares (grant or award)
- 4 Grant or award Director acquired 17,967 shares (grant or award)
- SC 13G Stake Amended Statement of Ownership
- 8-K Event Material agreement · Unregistered share sale
- 8-K Event Results of operations
- 10-Q Report Quarterly Report
- ARS Other Annual Report to Security Holders
- DEF 14A Proxy Proxy Statement
- 10-K Report Annual Report
- 8-K Event Results of operations
- 4 Grant or award Director acquired 16,185 shares (grant or award)
- 4 Grant or award Director acquired 18,685 shares (grant or award)
- 4 Grant or award Director acquired 15,790 shares (grant or award)
- 4 Grant or award Director acquired 18,816 shares (grant or award)
- 8-K Event Delisting notice
- SC 13D Stake Beneficial Ownership Report
- 8-K Event Material agreement · New debt or obligation
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 17,068 shares (grant or award)
Page 7 of 14 · 267 filings